Cortical lesions reflect brain damage in patients with MS [2]. However, the role of early cortical lesions in predicting long-term cognitive impairment has yet to be clarified. Therefore, the current study aimed to assess the prognostic capacity of cortical lesions at MS diagnosis regarding cognitive impairment after 20 years of MS. The study included 170 patients with MS, who received a 1.5T MRI scan within 3 years from MS diagnosis to evaluate cortical lesions. Furthermore, a neuropsychological assessment was conducted to assess cognitive status at 20 years follow-up. Mr Stefano Ziccardi (University of Verona, Italy) presented the study results.
Patients who were cognitively impaired at 20 years of follow-up had a significantly higher number of cortical lesions at diagnosis (median 3.0) than patients without cognitive impairment at follow-up (median 0.0). Moreover, there was a significant difference in the number of cortical lesions at diagnosis between patients with mild cognitive impairment (median 2.0) and patients with severe cognitive impairment (median 4.0). Logistic regression analysis showed that patients with ≥3 cortical lesions at diagnosis had approximately a 4-fold risk of cognitive impairment at follow-up (OR 3.70; 95% CI 1.8–7.5; P<0.001). In addition, these patients were at higher risk of severe cognitive impairment after 20 years of disease (OR 3.33; 95% CI 1.49–4.17; P=0.01). These results suggest that early cortical lesion evaluation in MS patients could predict cognitive alterations in the future. Early recognition of these lesions is necessary in order to improve the diagnosis and monitoring of cognitive abilities in patients with MS, and to enable swift interventions.
- Ziccardi S, et al. Cortical lesions at diagnosis predict cognitive impairment in multiple sclerosis: a 20-year follow-up study. OP49, ECTRIMS 2021 Virtual Congress, 13–15 October.
- Calabrese M, et al. Arch Neurol. 2009;66(9):1144–50.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« Applicability of sNfL measurement in clinical practice Next Article
High-sensitive biomarker detection in MS via novel ELISA assay »
« Applicability of sNfL measurement in clinical practice Next Article
High-sensitive biomarker detection in MS via novel ELISA assay »
Table of Contents: ECTRIMS 2021
Featured articles
Preliminary data shows positive results of ATA188 for progressive MS
COVID-19
MS patients at risk of hampered immune response after vaccination
Immunotherapy in MS does not influence COVID-19 severity and mortality
Anti-CD20 antibodies associated with worse COVID-19 outcomes
ECTRIMS-EAN consensus on vaccination in MS patients
Experimental Treatments
The role of astrocyte phenotypes in acute MS lesions
Promising results of intrathecal MSC-NTF cells in progressive MS
Preliminary data shows positive results of ATA188 for progressive MS
Evobrutinib reduces relapses and MRI lesion activity
Primary endpoint of opicinumab for relapsing MS not met in AFFINITY trial
Elezanumab did not outperform placebo in progressive and relapsing MS
Ibudilast reduced retinal atrophy in primary progressive MS
Treatment Trials and Strategies
ECTRIMS/EAN Clinical Guidelines on MS treatment: an update
Rituximab most effective initial MS therapy in Swedish real-world study
Ublituximab meets primary endpoint for relapsing MS
Dynamic scoring system aids decision to switch MS therapies early
Long-term suppression of MRI disease activity with ocrelizumab
Stopping DMT: when or if at all?
Biomarkers
Early predictors of disability progression in paediatric-onset MS
High-sensitive biomarker detection in MS via novel ELISA assay
Cortical lesions predict cognitive impairment 20 years after MS diagnosis
Applicability of sNfL measurement in clinical practice
MRI more sensitive for disease activity than relapses in SPMS
Imaging
Changes in GABA-receptor binding among cognitively impaired MS patients
T2 lesions independently predict early conversion to SPMS
Natural killer-like CD8+ T cells as a reservoir of clonal cells related to MS activity
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Eculizumab, satralizumab, or inebilizumab for NMOSD?
Long-term efficacy of satralizumab for NMOSD
Long-term efficacy data: inebilizumab for NMOSD
Progressive MS
Charcot Award 2021: Progressive MS, a personal perspective
Top score poster: Meta-analysis on the effect of DMTs
Cortical lesions predict disease progression and disability accumulation
Ocrelizumab shows long-term benefits in primary progressive MS
Other
WNT9B-gene variant associated with doubled relapse risk in MS
Melatonin associated with improved sleep quality in MS patients
“Expanded Disability Status Scale 0 is not normal”
Personality trait alterations in MS patients
Related Articles
December 4, 2023
Rate of grey matter brain atrophy accelerates after menopause
December 20, 2022
Comparing real-world effectiveness of DMTs
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com